BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21857254)

  • 1. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas.
    Sterlacci W; Tzankov A; Veits L; Zelger B; Bihl MP; Foerster A; Augustin F; Fiegl M; Savic S
    J Thorac Oncol; 2011 Oct; 6(10):1649-57. PubMed ID: 21857254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
    Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
    Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
    Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
    Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.
    Sterlacci W; Fiegl M; Hilbe W; Jamnig H; Oberaigner W; Schmid T; Augustin F; Auberger J; Obermann EC; Tzankov A
    J Thorac Oncol; 2010 Sep; 5(9):1325-36. PubMed ID: 20631637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
    Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
    Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas.
    Hong SM; Choi J; Ryu K; Ro JY; Yu E
    Arch Pathol Lab Med; 2006 Jan; 130(1):33-8. PubMed ID: 16390235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
    Brambilla E; Moro D; Gazzeri S; Brambilla C
    J Pathol; 1999 Aug; 188(4):351-60. PubMed ID: 10440744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
    Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
    J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
    Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
    Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of the p16(ink4a) gene in resected nonsmall cell lung tumors and exfoliated cells within sputum.
    Chen JT; Chen YC; Wang YC; Tseng RC; Chen CY; Wang YC
    Int J Cancer; 2002 Apr; 98(5):724-31. PubMed ID: 11920642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma.
    Khor GH; Froemming GR; Zain RB; Abraham MT; Omar E; Tan SK; Tan AC; Vincent-Chong VK; Thong KL
    Int J Med Sci; 2013; 10(12):1727-39. PubMed ID: 24155659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
    Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
    Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
    Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
    Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
    Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions.
    Breuer RH; Snijders PJ; Sutedja GT; Sewalt RG; Otte AP; Postmus PE; Meijer CJ; Raaphorst FM; Smit EF
    Lung Cancer; 2005 Jun; 48(3):299-306. PubMed ID: 15892997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
    Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
    Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
    Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients.
    Su CY; Chang YC; Chan YC; Lin TC; Huang MS; Yang CJ; Hsiao M
    Eur J Surg Oncol; 2014 Sep; 40(9):1143-50. PubMed ID: 24969958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.